Stakeholder Opinions: Fibromyalgia - Potentially lucrative market soon to become reality

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-05-16

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.


Scope

  • Analysis of the patient potential, main unmet needs, and clinical trial design in fibromyalgia, with an estimation of market size.
  • Insight into current treatment controversies, including referral and prescribing patterns across the seven major markets.
  • Detailed profiles of Cymbalta, Lyrica, and milnacipran for use in fibromyalgia, with indication-specific sales forecasts of these drugs to 2016.
  • Discussion of key fibromyalgia market drivers, such as strategies that improve public awareness and physician education.


    • Report Highlights
    Following FDA approvals, Datamonitor foresees a dramatic rise in market value resulting from an upsurge in diagnosis and treatment rates. Estimated at $367m in 2006 in the US and 5EU, the market is forecast to grow to $1.7 billion in 2016.

    Commercial success of new fibromyalgia brands will encourage other companies to consider investment, and will see the R&D pipeline for new therapies increase over the coming years. A defined regulatory pathway will also attract future investors.

    Polypharmacotherapy will become commonplace in fibromyalgia management and Lyrica with Cymbalta will be a popular combination. This is good news for Lilly and Pfizer as it will effectively expand their market by reducing competition.


    Reasons to Purchase

  • Quantify the future market size in order to weigh up the risk of investing in fibromyalgia or to validate internal forecasts for pipeline products.
  • Gain insight into opinion leaders' thoughts on the major opportunities and challenges facing the fibromyalgia market.
  • Assess the six major market (US and 5EU) sales forecasts of key late-stage pipeline drugs to 2016; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: Fibromyalgia pain fibromyalgia ibutamoren lyrica needs cymbalta comparison unmet and market opportunity

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.